<?xml version="1.0" encoding="UTF-8"?> <!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd"> <ArticleSet> <Article> <Journal> <PublisherName>journal-jmsr</PublisherName> <JournalTitle>Journal of Medical and Surgical Research</JournalTitle> <PISSN>I</PISSN> <EISSN>S</EISSN> <Volume-Issue>Vol. I, n 1 </Volume-Issue> <PartNumber/> <IssueTopic>Multidisciplinary</IssueTopic> <IssueLanguage>English</IssueLanguage> <Season>June, 2014</Season> <SpecialIssue>N</SpecialIssue> <SupplementaryIssue>N</SupplementaryIssue> <IssueOA>Y</IssueOA> <PubDate> <Year>-0001</Year> <Month>11</Month> <Day>30</Day> </PubDate> <ArticleType>JMSR Oncology</ArticleType> <ArticleTitle>Bilateral MALT (Mucosal Associated Lymphoid Tissue) Lymphoma of the Conjunctiva. A Rare Case Report</ArticleTitle> <SubTitle/> <ArticleLanguage>English</ArticleLanguage> <ArticleOA>Y</ArticleOA> <FirstPage>22</FirstPage> <LastPage>23</LastPage> <AuthorList> <Author> <FirstName>N. Alami</FirstName> <LastName>Drideb</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>N</CorrespondingAuthor> <ORCID/> <FirstName>H.</FirstName> <LastName>Eddou</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>K.</FirstName> <LastName>Doghmi</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>M.</FirstName> <LastName>Mikdame</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> </Author> </AuthorList> <DOI/> <Abstract>MALT (Mucosal Associated Lymphoid Tissue) lymphomas of the conjunctiva belong to the extranodal marginal zone B-cell lymphomas. This site, while standard, is uncommon. We present the observation of a 65 year__ampersandsign#39;s old man who presented a pink papular tumor developed on both lower eyelids. The CT-scan showed thickeni ng of soft tissues associated with bilateral eyelid and sub diaphragmatic nodes. A chemotherapy protocol based on eight courses of R-CHOP was established with a complete remission. Twelve months later, another bilateral eylid swelling reappeared. Treatment with local radiotherapy to 24 Gy was proposed with good outcome 28 months later.</Abstract> <AbstractLanguage>English</AbstractLanguage> <Keywords>Conjunctiva, Lymphoma, MALT , Rituximab</Keywords> <URLs> <Abstract>https://www.journal-jmsr.net/ubijournal-v1copy/journals/abstract.php?article_id=4684&title=Bilateral MALT (Mucosal Associated Lymphoid Tissue) Lymphoma of the Conjunctiva. A Rare Case Report</Abstract> </URLs> <References> <ReferencesarticleTitle>References</ReferencesarticleTitle> <ReferencesfirstPage>16</ReferencesfirstPage> <ReferenceslastPage>19</ReferenceslastPage> <References>1. Benabid. L et al. Les lymphomes malins non hodgkiniens conjonctivo-orbitaires. J Fr. Ophtalmol., 2005; 28, 10, 1058-1064. 2. Mannami T and al. Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia. Mod Pathol 2001;14:641-9. 3. Francesca Collina and al. Chlamydia psittaci in ocular adnexa MALT lymphoma: a possible role in lymphomagenesis and a different geographical distribution. Infectious Agents and Cancer 2012, 7:8. 4. Raderer M and al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 2000;83:454-7. 5. Gaucher D and al. MALT-type B-cell lymphoma masquerading as scleritis or posterior uveitis. J Fr Ophtalmol. 2005 Jan;28(1) 6. Voegtle R and al. MALT lymphoma of the lacrimal apparatus (mucosa-associated lymphoid tissue). J Fr Ophtalmol. 1999 Oct;22(8):884-7. 7. Benabid L et al. Nouvelle approche thand;eacute;rapeutique du lymphome malin non hodgkinien orbitaire : and;agrave; propos de deux cas traitand;eacute;s par rituximab. J Fr Ophtalmol, 2005;28:769-71. 8. Davies A and al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014 Feb 7. pii: S1470-2045(14)70005-1</References> </References> </Journal> </Article> </ArticleSet>